消化器内科学教室 スタッフ紹介

化学療法部 講師 Assistant Professor
石川 剛 Takeshi Ishikawa, M.D., Ph.D.

出身地 大阪府

略 歴

1994年 京都府立医科大学卒業
2003年 医学博士(京都府立医科大学大学院 甲第939)
2003年 京都府立洛東病院 京都府立医科大学消化器病態制御学助手併任
2004年 松下記念病院消化器科
2008年 国民健康保険新大江病院
2009年 京都府立医科大学消化器内科学・がん免疫細胞制御学 (講師)
2016年 京都府立医科大学附属病院・化学療法部(医員)、 京都府立医科大学大学院・消化器内科学(講師)
2018年~ 京都府立医科大学附属病院・化学療法部(副部長)

専 門

  • 消化器病学
  • 消化器内視鏡学
  • 臨床腫瘍学
  • 化学療法
  • がん免疫治療
  • 分子標的治療


  • 日本内科学会(総合内科専門医 12235)
  • 日本消化器病学会(専門医 27447、学会評議員、近畿支部評議員)
  • 日本消化器内視鏡学会(専門医 20030025、指導医20030025、近畿支部評議員)
  • 日本臨床腫瘍学会(がん薬物療法専門医 0800042, 指導医 1300015)
  • 日本バイオセラピィ学会 評議員
  • 日本癌学会、日本癌治療学会、日本がん免疫学、日本食道学会、日本胃癌学会
  • 日本ハイパーサーミア学会
  • American Association for Cancer Research (AACR) active member

業 績

  1. Ota T, Ishikawa T, Endo Y, Matsumura S, Yoshida J, Yasuda T, Okayama T, Inoue K, Dohi O, Yoshida N, Sakamoto N, Kamada K, Uchiyama K, Takagi T, Konishi H, Konishi H, Shiozaki A, Fujiwara H, Kishimoto M, Naito Y, Itoh Y. Skeletal muscle mass as a predictor of the response to neo-adjuvant chemotherapy in locally advanced esophageal cancer. Med Oncol. 2019 Jan 2;36(2):15. doi: 10.1007/s12032-018-1242-0. PubMed PMID: 30600347
  2. Ishikawa T, Okayama T, Sakamoto N, Ideno M, Oka K, Enoki T, Mineno J, Yoshida N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Konishi H, Kokura S, Uno K, Naito Y, Itoh Y. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. Int J Cancer. 2018 Jan 31. doi: 10.1002/ijc.31285.
  3. Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, Sato M, Morimoto S, Fujiki F, Eguchi H, Nagano H, Kumanogoh A, Unno M, Kon M, Shimada H, Ito K, Homma S, Oka Y, Morita S, Sugiyama H. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: A phase II randomized study. Cancer Immunol Res. 2018 Jan 22. pii: canimm.0386.2017. doi: 10.1158/2326-6066.CIR-17-0386. [Epub ahead of print] PubMed PMID: 29358173.
  4. Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Tabuchi Y, Kawano R, Yoshioka T, Yoshida N, Hosokawa T, Takayama K, Taguchi T. Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. Med Oncol. 2018 Apr 28;35(6):82.
  5. Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Kawano R, Tabuchi Y, Yoshioka T, Ihara N, Hosokawa T, Takayama K, Shikata K, Taguchi T. Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis. Med Oncol. 2018 Mar 16;35(4):55.
  6. Doi T, Ishikawa T, Okayama T, Oka K, Mizushima K, Yasuda T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Naito Y, Itoh Y. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep. 2017 Mar;37(3):1545-1554. doi:10.3892/or.2017.5399. Epub 2017 Jan 23. PubMed PMID: 28112370.
  7. Ishikawa T, Yasuda T, Doi T, Okayama T, Sakamoto N, Gen Y, Dohi O, Yoshida N, Kamada K, Uchiyama K, Handa O, Takagi T, Konishi H, Yagi N, Kokura S, Naito Y, Itoh Y. The amino-acid-rich elemental diet Elental® preserves lean body mass during chemo- or chemoradiotherapy for esophageal cancer. Oncol Rep. 2016 Aug;36(2):1093-100. doi: 10.3892/or.2016.4877. Epub 2016 Jun 15. PubMed PMID:27374272
  8. Sakamoto N, Ishikawa T, Kokura S, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015 Aug 25;13(1):277. doi:10.1186/ s12967-015-0632-8.
  9. Matsuyama T, Ishikawa T, Okayama T, et al. Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int J Cancer. 2015 May 27. doi: 10.1002/ijc.29620.
  10. Okayama T, Ishikawa T, Sugatani K., et al  Hypersensitivity Reactionsto Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol. Clin Ther. 2015 Jun 1;37(6):1259-69. doi: 10.1016/j.clinthera.2015.03.012.
  11. Ishikawa T, Adachi S, Okayama T,et al Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the anti-tumor activity of adoptive T-cell therapy when carried out with naïve rather than differentiated T-cells . Oncol Rep. 2015 Feb 24. doi: 10.3892/or.2015.3815.
  12. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytesin Patients with Recurrent Esophageal Cancer. Clin Cancer Res. 2015 May15;21(10):2268-77.
  13. Ishikawa T, Kokura S, Enoki T, et al. Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer. PLoS One. 2014 Jan 31;9(1):e83786.
  14. Kimura-Tsuchiya R, Ishikawa T, Kokura S, et al. The inhibitory effect of heat treatment against epithelial-mesenchymal transition(EMT) in human pancreatic adenocarcinoma cell lines. J Clin Biochem Nutr. 2014 Jul;55(1):56-61
  15. Uchiyama K, Ishikawa T, Sakamoto N, Kajikawa H, Takagi T, Handa O, Tatsumi Y, Yagi N, Naito Y, Itoh Y, Takemura S. Analysis of cardiopulmonary stress during endoscopy: is unsedated transnasal esophagogastroduodenoscopy appropriate for elderly patients? Can J Gastroenterol Hepatol. 2014 Jan;28(1):31-4.
  16. Ishikawa T, Kokura S, Sakamoto N, et al.Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. Int J Cancer 2013;133, 119-1126
  17. Ando T, Ishikawa T, Takagi T, et al. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. Helicobacter. 2013 18(2):158-64.
  18. Sakai H, Kokura S, Ishikawa T, et al. Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells. J Clin Biochem Nutr. 2013 Jan;52(1):64-71
  19. Okajima M, Kokura S, Ishikawa T, et al. Anoxia/reoxygenation induces epithelial-mesenchymal transition in human colon cancer cell lines. Oncol Rep 2013 Jun;29(6):2311-7
  20. Ishikawa T, Kokura S, Sakamoto N, et al. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int J Hyperthermia.2012;28(7):597-604
  21. Ishikawa T, Kokura S, Sakamoto N, et al. Relationship between circulating cytokine levels and physical or psychological functioning in patients with advanced cancer. Clin Biochem. 2012 Feb; 45(3):207-11
  22. Ishikawa T, Kokura S, Sakamoto N, et al. Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells Exp Ther Med. 2011 2: 737-743
  23. Ando T, Ishikawa T, Kato H, et al. Synergistic Effect of HLA Class II Loci and Cytokine Gene Polymorphisms on the Risk of Gastric Cancer in Japanese Patients with Helicobacter pylori Infection. Int J Cancer 2009 125, 2595-2602
  24. Ishikawa T, Ando T, Obayashi H, et al.  Helicobacter pylori isolated from a patient with Ménétrier’s disease increases hepatocyte growth factor mRNA expression in gastric fibroblasts: Comparison with Helicobacter pylori isolated from other gastric diseases. Dig.Dis.Sci. 2008 Jul;53(7):1785-91.
  25. Ishikawa T, Kokura S, Inui T, et al. Effects of sequential combination of hyperthermia and gemcitabine in the treatment of advanced unresectable pancreatic cancer: A retrospective study Thermal Medicine 2008;24:131-139
  26. Ando T, Ishikawa T, Kokura S, et al. Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype. Dig Dis Sci. 2008 Apr;53(4):933-7
  27. Ishikawa T, Yoshida N, Tokuda H, et al. Role of oxygen-derived free radicals in Helicobacter pylori water extract-induced mouse skin carcinogenesis. BioFactors, 2006; 28, 1-7
  28. Kokura S, Yoshida N, Ishikawa T, et al. Interleukin-10 plasmid DNA inhibits subcutaneous tumor growth of colon26 adenocarcinoma in mice. Cancer Letters 2005; 218, 171-179
  29. Ishikawa T, Yoshida N, Tokuda H, et al. Tumor initiating activity of Helicobacter pylori water extract on mouse skin carcinogenesis Cancer Letters 2003;191:41-47
  30. Ishikawa T, Yoshida N, Higashihara H, et al. Different effects of constitutive nitric oxide synthase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice. Clin Exp Metastasis. 2003;20(5):445-50.
  31. Yoshida N, Ishikawa T, Ichiishi E, et al. The effect of rebamipide on Helicobacter pylori extract-mediated changes of gene expression in gastric epithelial cells. Aliment Pharmacol Ther. 2003 Jul;18 Suppl 1:63-75.

〒602-8566 京都市上京区河原町通広小路上る梶井町465番地 京都府立医科大学消化器内科
TEL:075-251-5519(医局)FAX:075-251-0710(医局)消化器内科医局 mail: